1. Absorption and metabolism of tiliroside (kaempferol 3--D-(6''-p-coumaroyl)-glucopyranoside) and its related compounds kaempferol, kaempferol-3-glucoside and p-coumaric acid were investigated in the small intestinal Caco-2 cell model. Apparent permeation (P app ) was determined as 0.62  10 -6 cm/s, 3.1 10 -6 cm/s, 0 and 22.8 10 -6 cm/s respectively.
Abstract
1. Absorption and metabolism of tiliroside (kaempferol 3--D-(6''-p-coumaroyl)-glucopyranoside) and its related compounds kaempferol, kaempferol-3-glucoside and p-coumaric acid were investigated in the small intestinal Caco-2 cell model. Apparent permeation (P app ) was determined as 0.62  10 -6 cm/s, 3.1 10 -6 cm/s, 0 and 22.8 10 -6 cm/s respectively.
2. Mechanistic study showed that the transportation of tiliroside, kaempferol-3-glucoside and p-coumaric acid in Caco-2 model were transporter(s) involved, while transportation of kaempferol was solely by passive diffusion mechanism.
3. Efflux transporters, multi-drug-resistance-associated protein-2 (MRP2), was shown to play a role in limiting the uptake of tiliroside. Inhibitors of MRP2, (MK571 and rifampicin) and co-incubation with kaempferol (10 M), increased transfer from the apical to the basolateral side by three-five fold.
4. Metabolites of kaempferol-3-glucoside and p-coumaric acid were not detected in the current Caco-2 model, while tiliroside was metabolised to a limited extent, with two tiliroside mono-glucuronides identified; and kaempferol was metabolised to a higher extent, with three mono-glucuronides and two mono-sulfates identified.
5. In conclusion, tiliroside was metabolised and transported across Caco-2 cell membrane to a limited extent. Transportation could be increased by applying MRP2 inhibitors or co-incubation with kaempferol. It is proposed that tiliroside can be absorbed by human;
future pharmacokinetics studies are warranted in order to determine the usefulness of tiliroside as a bioactive agent.
Introduction
Tiliroside (kaempferol 3--D-(6''-p-coumaroyl)-glucopyranoside; Figure 1 ) is a flavonol ester present in a number of herbal plants (Nowak, 2003) and medicines (Leitão et al., 2000) , and present at a relatively low level in a number of foods, such as strawberry (Itoh et al., 2009 ),
Chinese raspberry (Chen et al., 2009) , and rosehip (Kumarasamy et al., 2003) . Increasing evidence from in vitro and in vivo animal studies show tiliroside may have health beneficial effects on human health, such as anti-inflammatory (Sala et al., 2003) , hepatoprotective (Matsuda et al., 2002) , and antidiabetic activity (Ninomiya et al., 2007) . In these studies (Matsuda et al., 2002; Ninomiya et al., 2007; Sala et al., 2003) , application of tiliroside at high doses (up to 100 mg/kg body wt) was given either orally or by intraperitoneal or subcutaneous injections to mice, and at all doses examined, tiliroside lead to positive effects.
In particular, lower levels of orally administered trans-tiliroside (0.1~10 mg/kg body wt/day) inhibited the gain of body weight (especially visceral fat weight), and reduced liver triglyceride, and free fatty acids levels without affecting food intake (Ninomiya et al., 2007) .
Longer term tiliroside intake (15 days) significantly suppressed the elevation of glucose levels in plasma after intraperitoneal injection of glucose (1g/kg) in mice (Ninomiya et al., 2007) .
It is of paramount importance when investigating bioactivity of flavonoids to understand bioavailability. Tiliroside absorption and metabolism has never previously been studied, and thus we have investigated the potential absorption of this flavonoid conjugate using an intestinal model system. Caco-2 cells are human colon adenocarcinoma cells that undergo spontaneous differentiation into monolayers of enterocytes in culture, with characteristics similar to the human intestinal epithelium (Polli et al., 2004) . Caco-2 cells have been the most popular in vitro cell-based model to predict drug permeability. Results from studies of the Caco-2 cell monolayer correlate well with the level of in vivo oral absorption in humans (Artursson and Karlsson, 1991) . The aim of our study was to investigate the transport and metabolism of tiliroside and related compounds (kaempferol, kaempferol-3-glucoside, and p-coumaric acid) across the Caco-2 intestinal cell model in order to predict absorption of tiliroside in humans. is a mixture of trans-and cis-isomers. The cis-isoform accounted for less than 4% of the trans-isoform of tiliroside at the concentration used in this study. Therefore, only trans-tiliroside is considered in this study. If not specified, tiliroside refers to trans-tiliroside in the later text. All flavonoids were HPLC grade, and prepared by first dissolving in DMSO (Sigma-Aldrich) at a high concentration (eg. 10 mM) and were then further diluted in HBSS to the desired concentration (eg. 10 M; DMSO <0.1% vol.) on the day of experiment.
Materials and Methods

Chemicals
L-Ascorbic acid, rifampicin, sodium hydroxide and hydrochloric acid were purchased from Sigma-Aldrich. MK571 (sodium salt) was purchased from Merck Chemicals Ltd.
Caco-2 cells
The human colon carcinoma cell line Caco-2 cells (HTB-37) was obtained from the American 
Absorption and metabolism studies
The medium was removed from both the apical and basolateral sides and washed with HBSS twice. Each compartment was replaced with 2 ml of the transport solution consisting of HBSS containing 1.8 mM calcium (required for maintaining integrity of the tight junctions), 1 mM ascorbic acid (required to prevent degradation of polyphenols), and either with or without polyphenols at the desired concentration. The pH was adjusted by using less than 1% of HCL or NaOH (3 M) to 6 on the apical side and 7.4 on basolateral side to mimic human intestinal physiological condition. After an incubation of 2 h (37°C, 5% CO 2 :95% O 2 ), the apical and basolateral solutions were collected, and each compartment was gently washed with 2 ml of HBSS three times. Experimental solution (2 ml) and wash solution (6 ml) from each compartment were collected and stored separately. Ascorbic acid (10 mM) was added and samples stored at -80°C until analysed by HPLC.
Apparent permeability coefficient (P app ) was calculated using the following equation (Walgren et al., 1998) :
Where, V= the volume of the solution in the receiving compartment, A= the membrane surface area, C0 = the initial concentration in the donor compartment, and dC/dT = the change in flavonoid concentration in the receiver solution over time. Data were expressed as the means ± standard deviation of at least three independent repeats. Differences in P app were evaluated using Student's t-test. A P value 0.05 was considered significant.
Time course study
Transport solution (2 ml) containing tiliroside or kaempferol was incubated with Caco-2 cells on either the apical or basolateral side. An aliquot (200 l) of medium was removed from each side of the compartment at 0, 30, 60, 90 and 120 min after incubation. These solutions were diluted 1:1 (v:v) with methanol and centrifuged (13 300 g, 10 min) before analysed by HPLC.
All experiments were individually repeated for at least 3 times.
Inhibition studies
After the HBSS wash, both compartments were replaced with transport solution (2 ml), with the inhibitors MK571 (50 M) or rifampicin (80 M) applied to the apical compartment. After 30 min pre-inhibition, solution from both compartments was removed and transport solution (2 ml) was replaced with the inhibitor applied to the apical compartment, and the polyphenol (10 M) applied to either the apical or basolateral compartment. After incubation (2 h), samples were collected and stored until analysed by HPLC. All experiments were individually repeated for at least 3 times. Differences in P app were evaluated using Student's t-test. A P value 0.05 was considered significant.
A similar study was carried out by co-incubating related polyphenols. The basolateral compartment was replaced with transport solution (2 ml), and the apical compartment had transport solution supplemented with either p-coumaric acid (10 M), or kaempferol (10 M), or the mixture of the two compounds (both at 10 M). After 30 min pre-inhibition, solution from both compartments were removed and replaced with identical solutions, but also including tiliroside (10 M) in the apical compartment. After incubation (2 h), samples were collected and stored until analysed by HPLC. All experiments were individually repeated for at least 3 times. Differences in P app were evaluated using Student's t-test. A P value 0.05 was considered significant.
Extraction
Frozen samples from storage were freeze-dried (Scanvac CoolSafeTM Freeze-Drier, Lynge).
Each sample was re-dissolved in methanol (2 mL) and vortexed using a Genie 2 vortex mixer (Scientific Industries, USA) operating at full speed for 2 min. Methanol extracts were sonicated (Clifton Ultrasonic Baths MU-14, UK; 30 min) and centrifuged (10 min, 13 300 g).
The supernatant was analysed by HPLC.
HPLC analysis
An Agilent 1200 series rapid resolution LC system comprising a thermostatic autosampler, column oven, vacuum degasser, gradient mixer and a binary pump coupled to a diode array detector was used for analysis of all samples. The HPLC was fitted with a C18 Zorbax Eclipse column XDB-C18 (4.6 x 50 mm; internal diameter 1.8 m; Agilent, Berkshire UK), and held at a constant temperature of 30°C, and the analysis was controlled by ChemStation software.
Solvents were A: trifluoroacetic acid (0.1%, HPLC grade) in purified water (Direct Q, Millipore, UK) and B: acetonitrile (100%; HPLC grade), and were run at a flow rate of 0.85 ml/min. The gradient system used was: 15% solvent B at 0 min, increasing to 40% at 3 min, and further increasing to 90% by 5 min. Solvent B was held at 90% for 1 min before decreasing to 15% by 6.5 min, and held at 15% until 8 min. Samples (10 l) were injected directly on to the column, and the needle was washed with methanol between injections to prevent sample crossover. The eluent was monitored between 200 and 450 nm by diode array.
Chromatograms were observed at the optimum wavelength corresponding to each compound.
LC-MS/MS analysis
The LC system in LC-MS/MS was modified slightly from the HPLC analysis. The solvents were: A: formic acid (0.1%, LC-MS grade) in purified water (Direct Q, Millipore, UK) and B:
acetonitrile (100%; LC-MS grade), and were run at a flow rate of 0.30 ml/min. The gradient system used was: 15% solvent B at 0 min, increasing to 40% at 8 min, and further increasing to 70% by 15 min, then increasing to 90% by 16 min. Solvent B was held at 90% for 1 min before decreasing to 15% by 17.5 min, and held at 15% until 30 min. Samples (5 l) were injected directly on to the column, and the needle was washed with methanol between injections to prevent sample crossover. The eluent was monitored between 200 and 450 nm by diode array.
MS was performed with an Agilent 6410 triple-quad LC-MS with electrospray source (Agilent Technologies) supplied by a N 2 generator (Peak Scientific, Inchinnan, UK). LC eluent was diverted to waste for the initial 3 min, the eluent then entered the electrospray nebulizer that ejected a N 2 flow (60 psi) into the spray chamber which set in negative ionization mode (ESI-). The solvent was removed with a source gas temperature of 350°C and a gas flow of 11 L/min. The capillary potential was 4000V, and the fragmentor potential was 135V. Quad 1 was set to filter an m/z of the ionized parent compound in unit resolution. The filtered compounds were then subjected to a collision energy set at a potential of 10~20V; 
Results
Transport across Caco-2 cells
The transportation of tiliroside and related compounds (kaempferol, kaempferol-3-glucoside and p-coumaric acid) following incubation of the compound on either the apical or basolateral side is summarized in Table 1 and the apparent permeation (P app ) of the compounds is shown in Figure 2 . A concentration of 10 M was selected for all compounds investigated as it is a relevant physiological concentration of polyphenol in humans (Williamson and Manach, 2005) .
As shown in Table 1 and Figure 2 , tiliroside had a low absorption (1%) from the apical (A) to basolateral (B) side, while it was approximately 7-fold greater from B to A. Kaempferol had a higher absorption (5%) than tiliroside, and transportation in both directions was equivalent.
These results were also demonstrated in the time course studies presented in Figure 3 . There was no observable transportation of kaempferol-3-glucoside from the A to B direction for Caco-2 cells, though transport of kaempferol-3-glucoside from B to A (4%) did occur.
p-Coumaric acid was found to have a high absorption across the Caco-2 cell model (A to B; 36%), although a lower level of transport occurred in the B to A direction (12%).
The recovery of tiliroside and p-coumaric acid in both chambers was good (~90%), however kaempferol-3-glucoside and kaempferol had lower recoveries (<70% and <50%, respectively).
The lower recoveries are probably, due at least in part, to insolubility at the concentration used. However kaempferol was also further metabolised.
Metabolism in Caco-2 cells
When p-coumaric acid and kaempferol-3-glucoside were incubated, only the parent compounds were observed in the apical and basolateral compartments. Figure 4 (a) shows a typical HPLC chromatogram of tiliroside in apical solution after incubation for 2 h with Caco-2 cells. There was evidence of metabolism of tiliroside, as several small new peaks (T1-T8) were observed (see Fig. 4b ), however these peaks accounted for less than 4% (based on peak area) of the total tiliroside. Only the main metabolites, T5 and T6, had sufficient signal for UV spectral analysis (Fig. 4c) . LC-MS/MS operated in negative mode found these two peaks had an identical molecular weight of 769 (the same mass as tiliroside monoglucuronides negative ion), and after application of 10 V collision energy the resultant product ions had a molecular weight of 593 (the same mass as tiliroside negative ion). T5 and T6 therefore were identified as tiliroside mono-glucuronides.
Following incubation of kaempferol for 2 h with Caco-2 cells, kaempferol and four new peaks (K1-K4) were identified by HPLC (see Figure 5a ) and LC-MS/MS. Based on kaempferol-3-glucoside standard approximately 35% of kaempferol was present as conjugate form. In negative mode, K1, K2, K3 were found to have an identical molecular weight of 461(the same mass as kaempferol mono-glucuronides negative ion) and after application of 10 V collision energy, all the resultant product ions had an identical molecular weight of 285 (the same mass as kaempferol negative ion). Thus, K1, K2 and K3 were identified as kaempferol mono-glucuronides Peak K4 had a molecular weight of 365 (the same mass as kaempferol mono-sulfate negative ion) and and after application of 10 V collision energy, the resultant product ion had a molecular weight of 285 (the same mass as kaempferol negative ion). Therefore, K4 was identified as kaempferol mono-sulfate. The molecular weights, in selected-ion monitoring (SIM) and product ion mode, for kaempferol glucurono-sulfate, kaempferol di-glucuronide, and kaempferol di-sulfates were assessed, but none of these potential metabolites were observed.
The UV absorption shift of the peak maxima corresponding to Band I of the metabolites, in relation to kaempferol, allows the position of conjugation to be determined (see Figure 5b ).
Only the 3-, 4-and 7-positions are available on kaempferol for conjugation, and both the 3-and 4-would cause a hypsochromic Band I shift. Conjugation at the 4-position would cause a small shift of 3-5 nm, while conjugation at the 3-position would cause larger shift of 12-17 nm (Day et al., 2000) . K1 has a Band I absorption maximum at 348 nm, a large shift in comparison to kaempferol, and hence can be identified as kaempferol-3-glucuronide. K2 has a band I absorption maximum at 368 nm, the same as kaempferol, therefore is likely to be kaempferol-7-glucuronide. K3 has a Band I absorption maximum at 362 nm (a small shift compared to kaempferol), indicating conjugation at the 4-position. K4 is a broad peak, and is likely to be a mixture of more than one sulfate. The UV spectra acquired at different positions of the HPLC peak showed different Band I absorption maxima; one at 368 nm and one at 364 nm. Thus, it is likely that kaempferol-7-sulfate and -4-sulfate were formed by the Caco-2 cells.
Inhibitors of transport
Known inhibitors of MRP2 efflux transporter, were incubated with either tiliroside or kaempferol. As shown in Figure 6 Tiliroside was also co-incubated with its potential breakdown compounds, kaempferol and p-coumaric acid. Figure 7 demonstrates that transfer of tiliroside from the apical to the basolateral compartment was significantly increased (3-fold) when kaempferol was co-incubated on the apical side, with or without p-coumaric acid. On its own p-coumaric acid had no effect on tiliroside transfer.
Discussion
Transport study
Tiliroside is a relatively hydrophobic compound, despite having a hydrophilic conjugating side chain (coumaroyl-glucoside), it has a Log P of 2.7 (Luo et al., 2011) . It is therefore feasible that tiliroside can diffuse across biological membranes. However tiliroside also has a large molecular weight (594), which exceeds the "rule of five" summarized by Lipinski (Lipinski et al., 1997) , in that compounds with a molecular mass greater than 500 are likely to be poorly absorbed. Tiliroside did, however, cross the Caco-2 cell model, with approximately 1% being transferred to the basolateral side; a higher rate of transfer was observed from the basolateral to the apical side, and the increase was time-dependent. This suggests that efflux transporter(s) are likely to be involved in pumping tiliroside back out of the intestinal cells, limiting the extent to which apical to basolateral transfer can occur.
For flavonoids, the efflux transporters MRP2 has been shown to contribute to limiting absorption; this transporter has been previously reported to be functionally expressed in
Caco-2 cells (Hunter et al., 1993; Maubon et al., 2007) . MK571 has been used as an MRP2
inhibitor in many studies (Walgren et al., 2000; O'Leary et al., 2003) . Recently, it was reported that MK571 was not specific to MRP2, but could both affect MRP2 and BCRP to different extents (Matsson et al., 2009) . By comparing behaviour of 122 drugs, Matsson et al., (2009) reported rifampicin as a highly specific inhibitor to MRP2, with less than 1% inhibition to BCRP. Therefore, MK571 and rifampicin were selected to inhibit MRP2.
When tiliroside was incubated with MK571 or rifampicin there was an increase in transfer from the apical to basolateral side of the Caco-2 cells (see Figure 6a) . Likewise, for MK571
and rifampicin (91 and 99% specific for MRP2, respectively (Matsson et al., 2009) ) the basolateral to apical efflux was significantly reduced. These results suggest that MRP2 is strongly involved in tiliroside efflux which consequently reduces absorption of tiliroside across the Caco-2 cells. Other transporters may also play a role and further investigations would need to address the extent of the non-MRP2 contribution.
Tiliroside could potentially be hydrolysed to either kaempferol-3-glucoside and coumaric acid, or kaempferol, and therefore it was interesting to compare the transfer of these related compounds in the same Caco-2 model. Kaempferol is more hydrophobic (log P = 3.2 (Luo et al., 2011) ) than tiliroside, with a lower molecular weight (286) and, thus would be expected to diffuse passively across biological membranes. We found that 5% of kaempferol aglycone was transferred from the apical to basolateral membrane, and that no significant difference in transfers were observed in both directions, at similar constant linear rates (see Figure 2 and 3b). Kaempferol transfer from both directions was not affected by the application of inhibitors of efflux transporters MRP2. This evidence is indicative of passive transport, and is consistent with a previously published study (Barrington et al., 2009 ).
Kaempferol-3-glucoside was not transported from the apical to basolateral side of the Caco-2 model, and kaempferol-3-glucoside is not a substrate of cytosolic -glucosidase (Day et al., 1998) but can be hydrolysed to kaempferol by lactase phlorizin hydrolase (LPH (Németh et al., 2003) ) at the lumen brush border. LPH is expressed at very low levels in Caco-2 cells (Chantret et al., 1994; Day et al., 2003) and therefore lack of hydrolysis and basolateral transfer of kaempferol-3-glucoside were anticipated. Furthermore, kaempferol-3-glucoside was transported from the basolateral to apical side of the Caco-2 cells, suggesting that efflux transporters are involved. Quercetin-4-glucoside was a substrate of MRP2 (Walgren et al., 2000) , and thus it is likely that kaempferol-3-glucoside is also a substrate.
p-Coumaric acid was found to have a significant apical to basolateral transfer (37%) of p-coumaric acid, and a lower basolateral efflux (12%), which is consistent with previously published work (Konishi and Shimizu, 2003; Konishi and Kobayashi, 2004; Poquet et al., 2008) . p-Coumaric acid is hydrophilic (Log P -0.65 (Luo et al., 2011) ) and has a relatively low molecular weight (164). It is possible that transportation occurs via paracellular tight junctions rather than by a transcellular route. A related phenolic acid, ferulic acid however, was proposed to be transported by transcellular passive diffusion (Poquet et al., 2008) . The degree of phenolic acid transport is associated with the extent of ionisation (Poquet et al., 2008) ; ionisation creates a concentration gradient across the intestinal cells allowing passive diffusion of the phenolic acid. It has also been proposed that facilitated transport of coumaric acid using a proton pump, which is only active across a concentration gradient (Konishi and Shimizu, 2003; Konishi and Kobayashi, 2004) .
Metabolism study
Tiliroside was metabolised in our experiments, but to a very limited extent. The main two metabolites were identified as mono-glucuronides. Kaempferol was metabolised to mono-sulfate(s) and mono-glucuronides by the Caco-2/HTB37 cell model, with approximately 35% being metabolised as assessed in the apical transport solution after 2 h.
Metabolism of kaempferol has been studied previously in Caco-2/TC7 cells (Barrington et al., 2009) , and here five metabolites were identified, including a kaempferol glucurono-sulfate.
Differences in results may be accounted for by the different Caco-2 clonal lines (Maubon et al., 2007) , and different passage numbers used, as these may result in altered expression of phase II enzymes isoforms and transporters. No metabolism was observed for kaempferol-3-glucoside and p-coumaric acid in the current Caco-2 model.
Co-incubation
Co-incubation of tiliroside with kaempferol significantly increased the transfer of tiliroside from the apical to the basolateral side, suggesting that kaempferol may improve tiliroside absorption. As absorption of tiliroside is mediated by MRP2, it is possible that kaempferol is indirectly inhibiting this transporter. Kaempferol itself is not a substrate of MRP2, though kaempferol metabolites are effluxed by MRP2. It is therefore logical to propose that the mechanism of increased absorption of tiliroside after co-incubation with kaempferol is a result of competitive inhibition of MRP2 efflux transporters by kaempferol metabolites.
Tiliroside, in the absence of inhibitors, is transferred from the apical to basolateral membranes with an apparent permeation of 0.62  10 -6 cm/s. By comparing 20 drugs with apparent permeability ranging from 5  10 -6 to 5  10 -8 cm/s (Artursson and Karlsson, 1991) , and 55 drugs with known human absorption value (Irvine et al., 1999) , a good correlation between oral absorption in human and the results in Caco-2 model was reported. Drugs that were absorbed to >1% but <100% had apparent permeability 0.1~1.0  10 -6 cm/s, and drugs that are absorbed to <1% had apparent permeability ≤ 1  10 -7 (Artursson and Karlsson, 1991) .
Thus, tiliroside would be expected to be absorbed in humans.
Several factors may limit absorption of tiliroside in the Caco-2 cells compared to the intact intestine. The relatively homogenous nature of enterocytes in the model system means that there is lack of mucus-producing goblet cells (Polli et al., 2004) . Consequently, there is an absence of a mucus layer which may limit the predicted absorption of hydrophobic compounds such as tiliroside. The mucus layer allows hydrophobic compounds to have more intimate contact with the intestinal epithelium and increase residence time at absorption sites (Schipper et al., 1999; Behrens et al., 2002) . Furthermore, although most influx and efflux transporters are all functionally expressed in Caco-2 cells, they are expressed to a different degree compared to the in vivo situation. Maubon (2007) reported that there was at least a five times higher mRNA expression of MRP2 efflux transporters between Caco-2 (HTB-37) and the human small intestine. As MRP2 is strongly involved in efflux of tiliroside, the Caco-2 cell model may significantly underestimate the degree of potential absorption in humans.
Conclusions
The present study provides evidence for absorption and metabolism of tiliroside in Caco-2 cells. Assuming a good correlation between apparent permeation in Caco-2 cells and oral absorption, tiliroside would be expected to be absorbed in the small intestine in humans. The efflux transporter, MRP2, appears to limit uptake, but as tiliroside often co-exists with kaempferol in foods, absorption of tiliroside may be increased. Tiliroside metabolism appears to be limited. Hence, tiliroside should be present in plasma after intake of tiliroside-rich foods or supplements. A human pharmacokinetic intervention study on the absorption of tiliroside is required to confirm the hypothesis. Polyphenols (10 µM) were applied to Caco-2 cells on the apical (pH 6) or basolateral side (pH 7.4) and transfer to opposite side was monitored by HPLC after a 2 h incubation, 37°C. Standard deviation is for a minimum of three transwell plates.* Value for kaempferol does not include kaempferol metabolites. 10µM of tiliroside, kaempferol, K3G, and p-coumaric acid is equivalent to 11.9 µg, 5.7 µg, 9.0 µg and 3.3 µg respectively under current condition applied. Transfer % = amount of compound in receiving compartment divided by total compound applied × 100%.
